Roche’s Tarceva Extends Time to Disease Progession in Lung Cancer Study

Roche Holding AG’s Tarceva medicine extended the time patients with a certain kind of newly diagnosed lung cancer lived without their disease getting worse in a late-stage study.
Bloomberg